Inventor
MEINKE ANDREAS
AT46 patents
⚠️ This page may combine multiple inventors who share the name “MEINKE ANDREAS”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
INTERCELL AG
14 patentsUS7438912B2Oct 21, 2008
S.agalactiae antigens I + II
INTERCELL AG46 citations94
US7485710B2Feb 3, 2009
Nucleic acids coding for adhesion factor of group B streptococcus, adhesion factors of group B streptococcus and further uses thereof
INTERCELL AG43 citations92
US8372411B2Feb 12, 2013
S. pneumoniae antigens
INTERCELL AG19 citations90
US7635487B2Dec 22, 2009
S. pneumoniae antigens
INTERCELL AG29 citations90
US7968297B2Jun 28, 2011
Method for identification, isolation and production of antigens to a specific pathogen
INTERCELL AG7 citations81
US7771728B2Aug 10, 2010
Method for identification, isolation and production of antigens to a specific pathogen
INTERCELL AG10 citations81
US7638136B2Dec 29, 2009
Streptococcus pyogene antigens
INTERCELL AG10 citations80
US7927607B2Apr 19, 2011
S. agalactiae antigens I and II
INTERCELL AG5 citations71
US7960533B2Jun 14, 2011
Nucleic acids coding for adhesion factor of group B Streptococcus, adhesion factors of group B Streptococcus and further uses thereof
INTERCELL AG5 citations70
US7628994B2Dec 8, 2009
S. epidermidis antigens
INTERCELL AG1 citations59
US8349336B2Jan 8, 2013
Streptococcus pyogenes antigens
INTERCELL AG0 citations48
US8343510B2Jan 1, 2013
Protective proteins of S. agalactiae, combinations thereof and methods of using the same
INTERCELL AG1 citations46
US8795690B2Aug 5, 2014
Protective proteins of S. agalactiae, combinations thereof and methods of using the same
INTERCELL AG0 citations45
US8372410B2Feb 12, 2013
S. epidermidis antigens
INTERCELL AG0 citations45
VALNEVA AUSTRIA GMBH
9 patentsUS9926343B2Mar 27, 2018
Mutant fragments of OspA and methods and uses relating thereto
VALNEVA AUSTRIA GMBH10 citations91
US11208439B2Dec 28, 2021
Mutant fragments of OspA and methods and uses relating thereto
VALNEVA AUSTRIA GMBH6 citations83
US11466058B2Oct 11, 2022
Mutant fragments of OspA and methods and uses relating thereto
VALNEVA AUSTRIA GMBH4 citations82
US10544194B2Jan 28, 2020
Mutant fragments of OspA and methods and uses relating thereto
VALNEVA AUSTRIA GMBH8 citations82
US12195501B2Jan 14, 2025
Mutant fragments of OspA and methods and uses relating thereto
VALNEVA AUSTRIA GMBH1 citations73
US12018054B2Jun 25, 2024
Multivalent OspA polypeptides and methods and uses relating thereto
VALNEVA AUSTRIA GMBH3 citations71
US11684669B2Jun 27, 2023
CpG-adjuvanted SARS-CoV-2 virus vaccine
VALNEVA AUSTRIA GMBH6 citations70
US12331084B2Jun 17, 2025
Multivalent OspA polypeptides and methods and uses relating thereto
VALNEVA AUSTRIA GMBH0 citations59
US8952135B2Feb 10, 2015
S. agalactiae antigens I and II
VALNEVA AUSTRIA GMBH0 citations50
MEINKE ANDREAS
9 patentsUS8449892B2May 28, 2013
S. agalactiae antigens I and II
MEINKE ANDREAS5 citations81
US8323660B2Dec 4, 2012
Method for identification, isolation and production of antigens to a specific pathogen
MEINKE ANDREAS7 citations80
US8715688B2May 6, 2014
Method for identification, isolation and production of antigens to a specific pathogen
MEINKE ANDREAS3 citations59
US8236325B2Aug 7, 2012
S. epidermidis antigens
MEINKE ANDREAS1 citations58
US8529910B2Sep 10, 2013
Enterococcus antigens
MEINKE ANDREAS0 citations50
US8431128B2Apr 30, 2013
Enterococcus antigens
MEINKE ANDREAS0 citations50
US8529911B2Sep 10, 2013
Small Streptococcus pyogenes antigens and their use
MEINKE ANDREAS0 citations45
US8241643B2Aug 14, 2012
Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto
MEINKE ANDREAS0 citations45
US8445001B2May 21, 2013
Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto
MEINKE ANDREAS0 citations44
VALNEVA SE
6 patentsUS12011477B2Jun 18, 2024
Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus CHIKV-delta5NSP3
VALNEVA SE1 citations71
US11357846B2Jun 14, 2022
Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus CHIKV-Delta5NP3
VALNEVA SE3 citations71
US11484587B2Nov 1, 2022
Method of producing pharmaceutical compositions comprising immunogenic Chikungunya virus CHIKV-Delta5nsP3
VALNEVA SE3 citations64
US12564625B2Mar 3, 2026
Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus CHIKV-Δ5nsP3
VALNEVA SE0 citations61
US12162909B2Dec 10, 2024
Subunit vaccine for treatment or prevention of a respiratory tract infection
VALNEVA SE0 citations59
US12162907B2Dec 10, 2024
Subunit vaccine for treatment or prevention of a respiratory tract infection
VALNEVA SE0 citations59